ATE333901T1 - Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin - Google Patents

Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin

Info

Publication number
ATE333901T1
ATE333901T1 AT01990621T AT01990621T ATE333901T1 AT E333901 T1 ATE333901 T1 AT E333901T1 AT 01990621 T AT01990621 T AT 01990621T AT 01990621 T AT01990621 T AT 01990621T AT E333901 T1 ATE333901 T1 AT E333901T1
Authority
AT
Austria
Prior art keywords
biguanine
metformin
arginine
pharmaceutical composition
diabetes
Prior art date
Application number
AT01990621T
Other languages
English (en)
Inventor
Jean-Robert Rapin
Dominique Halbitte
Original Assignee
Dospharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dospharma filed Critical Dospharma
Application granted granted Critical
Publication of ATE333901T1 publication Critical patent/ATE333901T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01990621T 2000-12-29 2001-12-31 Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin ATE333901T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0017332A FR2818906B1 (fr) 2000-12-29 2000-12-29 Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine

Publications (1)

Publication Number Publication Date
ATE333901T1 true ATE333901T1 (de) 2006-08-15

Family

ID=8858430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01990621T ATE333901T1 (de) 2000-12-29 2001-12-31 Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin

Country Status (15)

Country Link
US (2) US7265156B2 (de)
EP (1) EP1349578B1 (de)
JP (1) JP4477301B2 (de)
AT (1) ATE333901T1 (de)
CA (1) CA2435484A1 (de)
CY (1) CY1105736T1 (de)
DE (1) DE60121804T2 (de)
DK (1) DK1349578T3 (de)
ES (1) ES2271103T3 (de)
FR (1) FR2818906B1 (de)
NZ (1) NZ527206A (de)
PT (1) PT1349578E (de)
RU (1) RU2003123491A (de)
WO (1) WO2002053090A2 (de)
ZA (1) ZA200207761B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA030999B1 (ru) 2009-10-02 2018-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Применение фармацевтической композиции, включающей ингибитор дпп-4 и гидрохлорид метформина
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
EP3685839A1 (de) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
CN105277705A (zh) * 2014-07-24 2016-01-27 江苏维赛科技生物发展有限公司 一种检测双胍类药物残留的试剂盒的制备及其检测方法
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2037002A1 (en) 1969-04-30 1970-12-31 Roques Bernard N-substd biguanide pamoic acid salts prepn
FR2696740B1 (fr) * 1992-10-13 1994-12-30 Dospharma Sa Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments.
ATE261935T1 (de) * 1997-12-08 2004-04-15 Bristol Myers Squibb Co Neue metformin salze und verfahren
EP1063973B1 (de) * 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Zweiphasiges kontrolliertes verabreichungssystem für hochlösliche arzneimittel und verwandtes verfahren
DE69918105T2 (de) * 1998-04-29 2005-07-07 Sumitomo Pharmaceuticals Co., Ltd. Orale zubereitung enthaltend einen biguanid und eine organische säure
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
AU2001213150A1 (en) 2000-08-03 2002-02-18 Olga Evgenievna Kolesova Composition of metformin with succinic acid or salts thereof and method for treating diabetes

Also Published As

Publication number Publication date
EP1349578A2 (de) 2003-10-08
ES2271103T3 (es) 2007-04-16
EP1349578B1 (de) 2006-07-26
NZ527206A (en) 2006-12-22
WO2002053090A3 (fr) 2003-02-20
US20070265349A1 (en) 2007-11-15
DE60121804D1 (de) 2006-09-07
CA2435484A1 (fr) 2002-07-11
JP2004517105A (ja) 2004-06-10
DK1349578T3 (da) 2006-11-27
WO2002053090A2 (fr) 2002-07-11
US7265156B2 (en) 2007-09-04
PT1349578E (pt) 2006-12-29
RU2003123491A (ru) 2005-01-10
CY1105736T1 (el) 2010-12-22
ZA200207761B (en) 2004-05-28
DE60121804T2 (de) 2007-08-23
FR2818906A1 (fr) 2002-07-05
FR2818906B1 (fr) 2004-04-02
JP4477301B2 (ja) 2010-06-09
US20040097399A1 (en) 2004-05-20

Similar Documents

Publication Publication Date Title
DE60121804D1 (de) Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin
SE0001899D0 (sv) New compounds
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
IS2600B (is) Ný tríasólpýrimídínefnasambönd
SE9904505D0 (sv) Novel compounds
MX2007006397A (es) Derivados de tetrahidropirano.
EA200400432A1 (ru) Производные мочевины
EA200300323A1 (ru) ПРОИЗВОДНЫЕ ГУАНИДИНОБЕНЗАМИДА (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ ОПОСРЕДОВАННОГО mc4-r ЗАБОЛЕВАНИЯ (ВАРИАНТЫ)
SE0100901D0 (sv) New composition
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
CR6540A (es) Trifluorobutenos nematicidas
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
UA100005C2 (ru) Ингибиторы репликации вируса иммунодефицита человека
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
DE50202504D1 (de) Neue 4-aminofuropyrimidine und ihre verwendung
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
DE60235375D1 (de) Platinkomplexe und deren verwendung in der therapie
SE0101038D0 (sv) Novel compounds
MY134026A (en) ?-carboline derivatives and its pharmaceutical use against depression and anxiety
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
GB0212410D0 (en) Organic compounds
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1349578

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee